181 related articles for article (PubMed ID: 9635697)
21. The 1989 patterns of care study for prostate cancer: five-year outcomes.
Chuba PJ; Moughan J; Forman JD; Owen J; Hanks G
Int J Radiat Oncol Biol Phys; 2001 Jun; 50(2):325-34. PubMed ID: 11380218
[TBL] [Abstract][Full Text] [Related]
22. Is there a subset of patients with PSA > or = 20 ng/ml who do well after conformal beam radiotherapy?
Algan O; Pinover WH; Hanlon AL; Al-Saleem TI; Hanks GE
Radiat Oncol Investig; 1999; 7(2):106-10. PubMed ID: 10333251
[TBL] [Abstract][Full Text] [Related]
23. Results of high dose rate afterloading brachytherapy boost to conventional external beam radiation therapy for initial and locally advanced prostate cancer.
Pellizzon AC; Nadalin W; Salvajoli JV; Fogaroli RC; Novaes PE; Maia MA; Ferrigno R
Radiother Oncol; 2003 Feb; 66(2):167-72. PubMed ID: 12648788
[TBL] [Abstract][Full Text] [Related]
24. Modifying the American Society for Therapeutic Radiology and Oncology definition of biochemical failure to minimize the influence of backdating in patients with prostate cancer treated with 3-dimensional conformal radiation therapy alone.
Horwitz EM; Uzzo RG; Hanlon AL; Greenberg RE; Hanks GE; Pollack A
J Urol; 2003 Jun; 169(6):2153-7; discussion 2157-9. PubMed ID: 12771738
[TBL] [Abstract][Full Text] [Related]
25. Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial.
Martinez AA; Kestin LL; Stromberg JS; Gonzalez JA; Wallace M; Gustafson GS; Edmundson GK; Spencer W; Vicini FA
Int J Radiat Oncol Biol Phys; 2000 May; 47(2):343-52. PubMed ID: 10802358
[TBL] [Abstract][Full Text] [Related]
26. Patterns and fate of PSA bouncing following 3D-CRT.
Hanlon AL; Pinover WH; Horwitz EM; Hanks GE
Int J Radiat Oncol Biol Phys; 2001 Jul; 50(4):845-9. PubMed ID: 11429210
[TBL] [Abstract][Full Text] [Related]
27. Conformal technique dose escalation for prostate cancer: biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen > or = 10 NG/ML.
Hanks GE; Lee WR; Hanlon AL; Hunt M; Kaplan E; Epstein BE; Movsas B; Schultheiss TE
Int J Radiat Oncol Biol Phys; 1996 Jul; 35(5):861-8. PubMed ID: 8751393
[TBL] [Abstract][Full Text] [Related]
28. Stage T1c prostate cancer: a heterogeneous category with widely varying prognosis.
Hung AY; Levy L; Kuban DA
Cancer J; 2002; 8(6):440-4. PubMed ID: 12500852
[TBL] [Abstract][Full Text] [Related]
29. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome.
Kupelian PA; Buchsbaum JC; Elshaikh MA; Reddy CA; Klein EA
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):629-34. PubMed ID: 14529766
[TBL] [Abstract][Full Text] [Related]
30. 3D conformal radiation therapy (3DCRT) for high grade prostate cancer: a multi-institutional review.
Fiveash JB; Hanks G; Roach M; Wang S; Vigneault E; McLaughlin PW; Sandler HM
Int J Radiat Oncol Biol Phys; 2000 May; 47(2):335-42. PubMed ID: 10802357
[TBL] [Abstract][Full Text] [Related]
31. The 100-day PSA: usefulness as surrogate end point for biochemical disease-free survival after definitive radiotherapy of prostate cancer.
Johnstone PA; Williams SR; Riffenburgh RH
Prostate Cancer Prostatic Dis; 2004; 7(3):263-7. PubMed ID: 15289811
[TBL] [Abstract][Full Text] [Related]
32. Factors that influence biochemical failure after radiation therapy for stage T1c prostate cancer.
Mohideen MN; McCall AR; Feinstein J; Sidrys J; Bricker P; Luka S
Am J Clin Oncol; 1998 Feb; 21(1):6-11. PubMed ID: 9499260
[TBL] [Abstract][Full Text] [Related]
33. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
[TBL] [Abstract][Full Text] [Related]
34. Equivalent biochemical control and improved prostate-specific antigen nadir after permanent prostate seed implant brachytherapy versus high-dose three-dimensional conformal radiotherapy and high-dose conformal proton beam radiotherapy boost.
Jabbari S; Weinberg VK; Shinohara K; Speight JL; Gottschalk AR; Hsu IC; Pickett B; McLaughlin PW; Sandler HM; Roach M
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):36-42. PubMed ID: 19409729
[TBL] [Abstract][Full Text] [Related]
35. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
[TBL] [Abstract][Full Text] [Related]
36. Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era.
Kupelian PA; Buchsbaum JC; Patel C; Elshaikh M; Reddy CA; Zippe C; Klein EA
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):704-11. PubMed ID: 11849793
[TBL] [Abstract][Full Text] [Related]
37. Dose selection for prostate cancer patients based on dose comparison and dose response studies.
Hanks GE; Hanlon AL; Pinover WH; Horwitz EM; Price RA; Schultheiss T
Int J Radiat Oncol Biol Phys; 2000 Mar; 46(4):823-32. PubMed ID: 10705002
[TBL] [Abstract][Full Text] [Related]
38. Long-term results in three-dimensional conformal radiotherapy of localized prostate cancer at moderate dose (66 Gy).
Goldner G; Wachter S; Wachter-Gerstner N; Dieckmann K; Pötter R
Strahlenther Onkol; 2006 Sep; 182(9):537-42. PubMed ID: 16944376
[TBL] [Abstract][Full Text] [Related]
39. Hypofractionated conformal radiotherapy in carcinoma of the prostate: five-year outcome analysis.
Livsey JE; Cowan RA; Wylie JP; Swindell R; Read G; Khoo VS; Logue JP
Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1254-9. PubMed ID: 14630259
[TBL] [Abstract][Full Text] [Related]
40. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]